Related Experiment Video
Updated: Aug 14, 2026
10:56
Combining Human Organoids and Organ-on-a-Chip Technology to Model Intestinal Region-Specific Functionality
Published on: May 5, 2022
Patient-Derived Organoids in Gastrointestinal Disease: Current Applications, Limitations, and Future Perspectives
Amanda Caruso1,2, Yasmine Hamrouni1,2, Antonella Delvecchio1,3
1Department of Medicine and Surgery, LUM University "Giuseppe Degennaro", Casamassima, 70010 Bari, Italy.
International Journal of Molecular Sciences
|August 13, 2026
Summary
Patient-derived organoids (PDOs) offer advanced 3D human models for studying gastrointestinal diseases, improving research relevance. These models show promise for drug screening and personalized medicine, despite ongoing implementation challenges.
Area of Science:
- Gastroenterology and Hepatology
- Biomedical Engineering
- Regenerative Medicine
Background:
- Patient-derived organoids (PDOs) provide advanced 3D human models that mimic native gastrointestinal tissue structure, molecular profiles, and function.
- PDOs overcome limitations of traditional 2D cultures and animal models by preserving epithelial architecture, cellular diversity, and patient-specific genetics.
- Technological advancements like co-cultures and organ-on-chip platforms enhance PDOs' ability to model complex epithelial interactions.
Purpose of the Study:
- To review recent progress in gastrointestinal organoid technology.
- To highlight current applications and emerging experimental platforms.
- To discuss future perspectives for integrating organoid models into translational research and personalized medicine.
Main Methods:
- Review of recent literature on patient-derived organoid technology in gastrointestinal research.
- Analysis of advancements in organoid culture systems, including co-culture and organ-on-chip platforms.
- Evaluation of the applications of organoids in studying gastrointestinal physiology, disease mechanisms, and therapeutic strategies.
Main Results:
- Organoid technology has significantly advanced gastrointestinal disease research by providing physiologically relevant human models.
- Organoids facilitate mechanistic studies of epithelial barrier function, host-microbiota interactions, and endocrine signaling.
- PDOs show promise for drug screening, biomarker discovery, precision medicine, and regenerative therapies in various gastrointestinal disorders.
Conclusions:
- Patient-derived organoids represent a powerful tool for understanding gastrointestinal diseases and developing personalized treatments.
- Further development is needed to address challenges such as microenvironment representation, standardization, scalability, and clinical integration.
- Organoid technology holds significant potential to revolutionize translational research and clinical practice in gastroenterology.
